Advancements in Transplantation Medicine
A recent case study sheds light on a promising direction for transplant medicine. A man diagnosed with type 1 diabetes can now produce his own insulin, thanks to a transplant of genetically modified pancreatic cells—surprisingly, without the usual anti-rejection medications.
This research, conducted by teams from Sweden and the U.S., was published this week in the New England Journal of Medicine. The man, aged 42 and living with diabetes for many years, received donated islet cells that had been edited using CRISPR to evade the immune system. About four months post-surgery, these gene-edited cells were still generating insulin without triggering any immune response.
According to the study’s authors, “Our study, although preliminary, suggests that immune evasion is an alternative concept for the circumvention of allorejection.”
Individuals with type 1 diabetes face a serious challenge: their immune systems attack the pancreatic cells that produce insulin. While synthetic insulin can manage the disease, health complications often arise over time. Recently, there has been growing interest in whether islet cell transplants could offer a consistent internal source of insulin for those with type 1 diabetes—a genuine cure, provided that the cells remain viable over the long haul.
Initial clinical trials have shown promise, yet these transplants typically necessitate lifelong immunosuppressive treatments to protect the donated cells from the recipient’s immune system. While effective, these drugs weaken the body’s defenses against infections and other threats.
The researchers adopted an innovative strategy to avoid the need for these drugs. They first explored it in mice and monkeys, making this particular case the first human application of their approach.
They modified the donated cells in three ways, aiming to suppress possible immune reactions. Two modifications reduced the presence of HLA class I and II antigens—proteins that signal to T cells that a cell may be foreign. A third adjustment increased levels of CD47, a protein that helps prevent the immune response from targeting these cells.
The modified cells were injected into the man’s forearm. Some of the edits were not entirely effective in all cells, leading to a rapid rejection of those cells by his immune system. However, the fully modified cells appeared to evade detection, functioning normally without immunosuppressants. Twelve weeks later, these survivor cells were still making insulin, and the man seemed to be doing well overall. He did have some minor issues, like mildly inflamed veins from the catheter, but nothing serious related to the transplant.
It’s important to note that this study serves primarily as a proof of concept. It demonstrates that the procedure can be executed safely, but it doesn’t prove its efficacy yet. The man received a relatively low number of donated cells, likely insufficient for him to stop his insulin therapy entirely. Follow-up research is necessary to determine if these cells can maintain their function over time.
Nonetheless, there’s much reason for optimism. This case represents the latest indication that researchers are closing in on a potential cure for type 1 diabetes. Other teams are seeing early success with similar transplant methods, some of which also manage to eliminate the need for immunosuppressant drugs.
